Results 41 to 50 of about 5,485 (197)

Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study

Frontiers in Oncology, 2023
IntroductionMitotane, the only drug approved by the Food and Drug Administration (FDA) for the treatment of adrenocortical carcinoma, is associated with several side effects including neurotoxicity. The aim of our study is to investigate the relationship
Marilda Mormando, Edvina Galiè, Marta Bianchini, Rosa Lauretta, Giulia Puliani, Antonio Tanzilli, Umberto Anceschi, Giuseppe Simone, Gianluca Petreri, Giuliana Graziano, Andrea Pace, Marialuisa Appetecchia   +11 more
doaj   +1 more source

Isosexual precocious pseudopuberty during mitotane treatment in a child with adrenocortical carcinoma: A case report

Pediatric Hematology Oncology Journal
Background: Mitotane is employed as adjuvant therapy in managing adrenocortical carcinoma in pediatric patients. While various adverse effects, such as estrogen-like manifestations, are well-documented in adults, there is limited knowledge regarding ...
Maria Riedmeier, Sonir Antonini, Clemens Benoit, Cheri L. Deal, Fassnacht Martin, Bonald C. Figueiredo, Elmas Nazli Gonc, Christoph Härtel, Jan Idkowiak, Max Kurlbaum, Ronald de Krijger, Raul C. Ribeiro, Jaydira del Rivero, Paul-Gerhardt Schlegel, Lester D.R. Thompson, Bilgehan Yalcin, Verena Wiegering   +16 more
doaj   +1 more source

Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor

Endocrinology, Diabetes & Metabolism Case Reports, 2018
Adrenocortical carcinoma (ACC) during childhood is a rare malignant tumor that frequently results in glucocorticoid and/or androgen excess. When there are signs of microscopic or macroscopic residual disease, adjuvant therapy is recommended with mitotane,
Philip D Oddie, Benjamin B Albert, Paul L Hofman, Craig Jefferies, Stephen Laughton, Philippa J Carter   +5 more
doaj   +1 more source

Multimodal Cross‐Attentive Graph‐Based Framework for Predicting In Vivo Endocrine Disruptors

Advanced Science, Volume 13, Issue 21, 13 April 2026.
A multimodal cross‐attentive graph neural network integrates molecular graphs with androgen and estrogen adverse outcome pathway (AOP)–anchored in vitro assay signals to predict in vivo endocrine disruption. By fusing information on Tier‐1 AOP logits with chemical structures, the framework achieves high accuracy and provides assay‐traceable ...
Eder Soares de Almeida Santos, Gustavo Felizardo Santos Sandes, Artur Christian Garcia da Silva, Holli‐Joi Martin, Eugene N. Muratov, Rodolpho de Campos Braga, Bruno Junior Neves   +6 more
wiley   +1 more source

Clinical results of the use of mitotane for adrenocortical carcinoma

Brazilian Journal of Medical and Biological Research, 2000
Mitotane (o,p'-DDD) acts mainly as an inhibitor of intramitochondrial pregnenolone and cortisol synthesis. Its adrenolytic effect depends on metabolic activation due to conversion to o,p'-DDA and o,p'-DDE.
A.A. Kasperlik-Zaluska
doaj   +1 more source

Pregnane X Receptor Regulates Human Endocrine System by Inducing Sex Hormone–Binding Globulin Expression

Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 4, April 2026.
ABSTRACT Sex hormone–binding globulin (SHBG) is a sex hormone carrier. We aimed to characterize the role of pregnane X receptor (PXR), a major regulator of drug metabolism, in SHBG regulation. Serum SHBG was measured in four clinical trials (n = 61) and expression in in vitro experiments in human 3D hepatocyte spheroids and HepG2 cells.
Maria H. Ahonen, Anja Konzack, Tomas Smutny, Petr Pavek, Jukka Hakkola, Janne Hukkanen   +5 more
wiley   +1 more source

Mitotane (op’DDD) restores growth and puberty in nine children with Cushing’s disease

Endocrine Connections, 2018
To investigate whether low-dose mitotane (up to 2 g/day) could be a temporary therapeutic alternative to transsphenoidal surgery (TSS) in pediatric Cushing’s disease (CD). Twenty-eight patients with CD aged 12.2 years (± 2.2) were referred to our center.
Emmanuelle Motte, Anya Rothenbuhler, Stephan Gaillard, Najiba Lahlou, Cécile Teinturier, Régis Coutant, Agnès Linglart   +6 more
doaj   +1 more source

Synthesis of β‐ 3 H‐mitotane for use in a rapid assay for mitotane metabolism [PDF]

, 1995
A 3 H + ‐release method has been developed for the assay of β‐hydroxylation of the adrenolytic drug mitotane. β‐ 3 H‐mitotane was synthesized by the reduction of 1‐(2‐chlorophenyl)‐1‐(4‐chlorophenyl)‐2,2,2‐trichloroethane by an aluminium‐Hg 2 Cl 2 ...
Counsell, Raymond E., Piñeiro‐sánchez, Mayra L., Ruyan, Mohamed K., Schteingart, David E., Sinsheimerl, Joseph E., Vaz, Alfin D. N.   +5 more
core   +1 more source

Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog

Veterinary Medicine and Science, 2021
Background Occult (or atypical) hyperadrenocorticism (HAC) shows clinical signs and laboratory abnormalities similar to classic hyperadrenocorticism, but normal signs in routine screening tests such as the corticotropin (ACTH) stimulation test and low ...
Su‐Min Park, Kyeong‐Bo Kim, Woo‐Jin Song, Hwa‐Young Youn   +3 more
doaj   +1 more source

Complete Remission of Advanced Adrenocortical Cancer Following Mitotane Monotherapy: A Case Report and Literature Review of Predictive Markers

Frontiers in Oncology, 2021
Mitotane has been used for the treatment of adrenocortical cancer (ACC) for over 50 years. Despite its widespread use both in monotherapy and in combination with chemotherapeutics, our knowledge of its mechanism of action and therapeutic efficacy is ...
Judit Tőke, Zsuzsanna Jakab, Júlia Stark, Gergely Huszty, Péter Reismann, Miklós Tóth   +5 more
doaj   +1 more source